CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies

Frontiers in Bioscience - Scholar

Volumn 2 S, Issue 3, 2010, Pages 980-992

  Kelley, Todd W ^a,b   Parker, Charles J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP LABORATORIES   (United States)

Author keywords

Biomarkers; FOXP3; Leukemia; Lymphoma; Myelodysplastic syndrome; Myeloproliferative neoplasm; Review; Tregs

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ACUTE DISEASE; ANIMAL; APLASTIC ANEMIA; BLOOD DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLASSIFICATION; CUTANEOUS T CELL LYMPHOMA; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; IMMUNOLOGY; LARGE CELL LYMPHOMA; LEUKEMIA; MALE; METABOLISM; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEOPLASM; REGULATORY T LYMPHOCYTE; REVIEW;

ACUTE DISEASE; ANEMIA, APLASTIC; ANIMALS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEMATOLOGIC NEOPLASMS; HODGKIN DISEASE; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 77956620494     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s114     Document Type: Article

References (100)

1. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol, 10, 1969-1980 (1998) (Pubitemid 28566059)
2. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita and E. Nakayama: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res, 59, 3128-3133 (1999) (Pubitemid 29316012)
3. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev, 182, 18-32 (2001) (Pubitemid 33070205)
4. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol, 163, 5211-5218 (1999)
5. + TCR transgenic T cells that mediate linked suppression of CD8+ T cell responses. J Immunol, 179, 2105-2114 (2007)
6. + regulatory T cell activity in both humans and mice. J Immunol 172, 834-842 (2004) (Pubitemid 38113739)
7. Fu, S., N. Zhang, A. C. Yopp, D. Chen, M. Mao, D. Chen, H. Zhang, Y. Ding and J. S. Bromberg: TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25-precursors. Am J Transplant, 4, 1614-27 (2004) (Pubitemid 39312295)
8. + regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol, 174, 1783-1786 (2005) (Pubitemid 40223916)
9. Cao, X., S. F. Cai, T. A. Fehniger, J. Song, L. I. Collins, D. R. Piwnica-Worms and T. J. Ley: Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity, 27, 635-646 (2007) (Pubitemid 47628832)
10. Gondek, D. C., V. Devries, E. C. Nowak, L. F. Lu, K. A. Bennett, Z. A. Scott and R. J. Noelle: Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells. J Immunol, 181, 4752-4760 (2008)
11. + regulatory T-cell-mediated suppression. Immunology, 118, 240-249 (2006) (Pubitemid 43727429)
12. Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M. L. Belladonna, R. Bianchi, M. C. Fioretti and P. Puccetti: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol, 3, 1097-1101 (2002) (Pubitemid 35363664)
13. Bennett, C. L., J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. Saulsbury, P. F. Chance and H. D. Ochs: The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 27, 20-21 (2001) (Pubitemid 32044513)
14. Gambineri, E., T. R. Torgerson and H. D. Ochs: Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol, 15, 430-435 (2003) (Pubitemid 36774255)
15. Seo, S. J., M. L. Fields, J. L. Buckler, A. J. Reed, L. Mandik-Nayak, S. A. Nish, R. J. Noelle, L. A. Turka, F. D. Finkelman, A. J. Caton and J. Erikson: The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity, 16, 535-546 (2002) (Pubitemid 34442578)
16. + regulatory T cells. J Immunol, 175, 4180-4183 (2005) (Pubitemid 41361949)
17. Iikuni, N., E. V. Lourenco, B. H. Hahn and A. La Cava: Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol, 183, 1518-1522 (2009)
18. + T cells selectively kill B lymphocytes. Blood, 107, 3925-3932 (2006) (Pubitemid 43726798)
19. + regulatory T cells. Nat Immunol, 4, 330-336 (2003) (Pubitemid 36432314)
20. +25high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation. Blood, 113, 5689-5691 (2009)
21. Godfrey, V. L., J. E. Wilkinson and L. B. Russell: X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol, 138, 1379-1387 (1991)
22. Hu, H., I. Djuretic, M. S. Sundrud and A. Rao: Transcriptional partners in regulatory T cells: Foxp3, Runx and NFAT. Trends Immunol, 28, 329-332 (2007) (Pubitemid 47077927)
23. Aarts-Riemens, T., M. E. Emmelot, L. F. Verdonck and T. Mutis: Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4 (+)CD25 (-) cells. Eur J Immunol, 38, 1381-1390 (2008)
24. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M. L. Disis, K. L. Knutson, L. Chen and W. Zou: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10, 942-949 (2004) (Pubitemid 39273735)
25. Ebelt, K., G. Babaryka, B. Frankenberger, C. G. Stief, W. Eisenmenger, T. Kirchner, D. J. Schendel and E. Noessner: Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer, 45, 1664-1672 (2009)
26. Salama, P., M. Phillips, F. Grieu, M. Morris, N. Zeps, D. Joseph, C. Platell and B. Iacopetta: Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol, 27, 186-192 (2009)
27. Gobert, M., I. Treilleux, N. Bendriss-Vermare, T. Bachelot, S. Goddard-Leon, V. Arfi, C. Biota, A. C. Doffin, I. Durand, D. Olive, S. Perez, N. Pasqual, C. Faure, I. Ray-Coquard, A. Puisieux, C. Caux, J. Y. Blay and C. Menetrier-Caux: Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res, 69, 2000-2009 (2009)
28. Olkhanud, p. B., D. Baatar, M. Bodogai, F. Hakim, R. Gress, R. L. Anderson, J. Deng, M. Xu, S. Briest and A. Biragyn: Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res, 69, 5996-6004 (2009)
29. Aruga, T., E. Suzuki, S. Saji, S. Horiguchi, K. Horiguchi, S. Sekine, D. Kitagawa, N. Funata, M. Toi, K. Sugihara and K. Kuroi: A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep, 22, 273-278 (2009)
30. Bohling, S. D. and K. H. Allison: Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol, 21, 1527-1532 (2008)
31. Perrone, G., P. A. Ruffini, V. Catalano, C. Spino, D. Santini, P. Muretto, C. Spoto, C. Zingaretti, V. Sisti, P. Alessandroni, P. Giordani, A. Cicetti, S. D'Emidio, S. Morini, A. Ruzzo, M. Magnani, G. Tonini, C. Rabitti and F. Graziano: Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer, 44, 1875-1882 (2008)
32. Zhou, J., T. Ding, W. Pan, L. Y. Zhu, L. Li and L. Zheng: Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer, 125, 1640-1648 (2009)
33. Gao, Q., S. J. Qiu, J. Fan, J. Zhou, X. Y. Wang, Y. S. Xiao, Y. Xu, Y. W. Li and Z. Y. Tang: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol, 25, 2586-2593 (2007) (Pubitemid 47041232)
34. Sato, E., S. H. Olson, J. Ahn, B. Bundy, H. Nishikawa, F. Qian, A. A. Jungbluth, D. Frosina, S. Gnjatic, C. Ambrosone, J. Kepner, T. Odunsi, G. Ritter, S. Lele, Y. T. Chen, H. Ohtani, L. J. Old and K. Odunsi: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA, 102, 18538-18543 (2005) (Pubitemid 43011261)
35. Sinicrope, F. A., R. L. Rego, S. M. Ansell, K. L. Knutson, N. R. Foster and D. J. Sargent: A Low Intraepithelial Effector (CD3 (+))/Regulatory (FoxP3 (+)) T-Cell Ratio Predicts Adverse Outcome of Human Colon Carcinoma. Gastroenterology, 137, 1270-1279 (2009)
36. Beyer, M. and J. L. Schultze: Regulatory T cells in cancer. Blood, 108, 804-811 (2006) (Pubitemid 44154611)
37. Dannull, J., Z. Su, D. Rizzieri, B. K. Yang, D. Coleman, D. Yancey, A. Zhang, P. Dahm, N. Chao, E. Gilboa and J. Vieweg: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest, 115, 3623-3633 (2005) (Pubitemid 43121851)
38. Dave, S. S., G. Wright, B. Tan, A. Rosenwald, R. D. Gascoyne, W. C. Chan, R. I. Fisher, R. M. Braziel, L. M. Rimsza, T. M. Grogan, T. p. Miller, M. LeBlanc, T. C. Greiner, D. D. Weisenburger, J. C. Lynch, J. Vose, J. O. Armitage, E. B. Smeland, S. Kvaloy, H. Holte, J. Delabie, J. M. Connors, P. M. Lansdorp, Q. Ouyang, T. A. Lister, A. J. Davies, A. J. Norton, H. K. Muller-Hermelink, G. Ott, E. Campo, E. Montserrat, W. H. Wilson, E. S. Jaffe, R. Simon, L. Yang, J. Powell, H. Zhao, N. Goldschmidt, M. Chiorazzi and L. M. Staudt: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med, 351, 2159-2169 (2004) (Pubitemid 39507628)
39. Kelley, T., R. Beck, A. Absi, T. Jin, B. Pohlman and E. Hsi: Biologic predictors in follicular lymphoma: importance of markers of immune response. Leuk Lymphoma, 48, 2403-2411 (2007) (Pubitemid 350253472)
40. Farinha, P., H. Masoudi, B. F. Skinnider, K. Shumansky, J. J. Spinelli, K. Gill, R. Klasa, N. Voss, J. M. Connors and R. D. Gascoyne: Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood, 106, 2169-2174 (2005) (Pubitemid 41291735)
41. Canioni, D., G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchhauser, T. Lamy, A. Sonet, M. C. Rousselet, C. Foussard and L. Xerri: High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol, 26, 440-446 (2008) (Pubitemid 351171697)
42. Byers, R. J., E. Sakhinia, P. Joseph, C. Glennie, J. A. Hoyland, L. p. Menasce, J. A. Radford and T. Illidge: Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood, 111, 4764-4770 (2008)
43. Carreras, J., A. Lopez-Guillermo, G. Roncador, N. Villamor, L. Colomo, A. Martinez, R. Hamoudi, W. J. Howat, E. Montserrat and E. Campo: High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol, 27, 1470-1476 (2009)
44. Carreras, J., A. Lopez-Guillermo, B. C. Fox, L. Colomo, A. Martinez, G. Roncador, E. Montserrat, E. Campo and A. H. Banham: High numbers of tumor infiltrating FOXP3-positive regulatory T-cells are associated with improved overall survival in follicular lymphoma. Blood, 108, 2957-2964 (2006)
45. Tzankov, A., C. Meier, P. Hirschmann, P. Went, S. A. Pileri and S. Dirnhofer: Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica, 93, 193-200 (2008) (Pubitemid 351397707)
46. + cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol, 24, 5052-5059 (2006) (Pubitemid 46631409)
47. Alvaro, T., M. Lejeune, M. T. Salvado, C. Lopez, J. Jaen, R. Bosch and L. E. Pons: Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol, 24, 5350-5357 (2006) (Pubitemid 46623165)
48. + Cells and Location of Forkhead Box Protein P3-Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome. J Clin Oncol, 24, 5052-5059 (2006) (Pubitemid 46631409)
49. de Jong, D., A. Koster, A. Hagenbeek, J. Raemaekers, D. Veldhuizen, S. Heisterkamp, J. p. de Boer and M. van Glabbeke: Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica, 94, 70-77 (2009)
50. Farinha, P., A. Al-Tourah, K. Gill, R. Klasa, J. M. Connors and R. D. Gascoyne: The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood, Nov 9 epub (2009)
51. Schwering, I., A. Brauninger, U. Klein, B. Jungnickel, M. Tinguely, V. Diehl, M. L. Hansmann, R. Dalla-Favera, K. Rajewsky and R. Kuppers: Loss of the B-lineage-specific gene expression program in Hodgkin and ReedSternberg cells of Hodgkin lymphoma. Blood, 101, 1505-1512 (2003) (Pubitemid 36182527)
52. Kelley, T. W., B. Pohlman, P. Elson and E. D. Hsi: The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol, 128, 958-965 (2007)
53. Alvaro, T., M. Lejeune, M. T. Salvado, R. Bosch, J. F. Garcia, J. Jaen, A. H. Banham, G. Roncador, C. Montalban and M. A. Piris: Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res, 11, 1467-1473 (2005) (Pubitemid 40315228)
54. Oudejans, J. J., N. M. Jiwa, J. A. Kummer, G. J. Ossenkoppele, P. van Heerde, J. W. Baars, P. M. Kluin, J. C. Kluin-Nelemans, P. J. van Diest, J. M. Middeldorp and C. J. Meijer: Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood, 89, 1376-1382 (1997) (Pubitemid 27080002)
55. Muenst, S., S. Hoeller, S. Dirnhofer and A. Tzankov: Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol, 40, 1715-1722 (2009)
56. Schreck, S., D. Friebel, M. Buettner, L. Distel, G. Grabenbauer, L. S. Young and G. Niedobitek: Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol, 27, 31-39 (2009)
57. Yamamoto, R., M. Nishikori, T. Kitawaki, T. Sakai, M. Hishizawa, M. Tashima, T. Kondo, K. Ohmori, M. Kurata, T. Hayashi and T. Uchiyama: PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood, 111, 3220-3224 (2008)
58. Alizadeh, A. A., M. B. Eisen, R. E. Davis, C. Ma, I. S. Lossos, A. Rosenwald, J. C. Boldrick, H. Sabet, T. Tran, X. Yu, J. I. Powell, L. Yang, G. E. Marti, T. Moore, J. Hudson Jr., L. Lu, D. B. Lewis, R. Tibshirani, G. Sherlock, W. C. Chan, T. C. Greiner, D. D. Weisenburger, J. O. Armitage, R. Warnke, R. Levy, W. Wilson, M. R. Grever, J. C. Byrd, D. Botstein, P. O. Brown and L. M. Staudt: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-511 (2000) (Pubitemid 30082188)
59. Hans, C. P., D. D. Weisenburger, T. C. Greiner, R. D. Gascoyne, J. Delabie, G. Ott, H. K. Muller-Hermelink, E. Campo, R. M. Braziel, E. S. Jaffe, Z. Pan, P. Farinha, L. M. Smith, B. Falini, A. H. Banham, A. Rosenwald, L. M. Staudt, J. M. Connors, J. O. Armitage and W. C. Chan: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282 (2004) (Pubitemid 38029949)
60. Nyman, H., M. Adde, M. L. Karjalainen-Lindsberg, M. Taskinen, M. Berglund, R. M. Amini, C. Blomqvist, G. Enblad and S. Leppa: Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood, 109, 4930-4935 (2007) (Pubitemid 46827791)
61. Hasselblom, S., M. Sigurdadottir, U. Hansson, H. Nilsson-Ehle, B. Ridell and P. O. Andersson: The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol, 137, 364-373 (2007) (Pubitemid 46650261)
62. Lee, N. R., E. K. Song, K. Y. Jang, H. N. Choi, W. S. Moon, K. Kwon, J. H. Lee, C. Y. Yim and J. Y. Kwak: Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma, 49, 247-256 (2008) (Pubitemid 351193916)
63. Saez, A. I., M. Garcia-Cosio, A. J. Saez, J. M. Hernandez, L. Sanchez-Verde, D. Alvarez, P. de la Cueva, R. Arranz, E. Conde, C. Grande, J. Rodriguez, D. Caballero and M. A. Piris: Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma. Leuk Lymphoma, 50, 571-581 (2009)
64. Gjerdrum, L. M., A. Woetmann, N. Odum, C. M. Burton, K. Rossen, G. L. Skovgaard, L. p. Ryder and E. Ralfkiaer: FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia, 21, 2512-2518 (2007) (Pubitemid 350148895)
65. Kim, W. Y., Y. K. Jeon, T. M. Kim, J. E. Kim, Y. A. Kim, S. H. Lee, D. W. Kim, D. S. Heo and C. W. Kim: Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol, 20, 1688-1696 (2009)
66. +FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol, 126, 2217-2223 (2006) (Pubitemid 44413168)
67. Curti, A., S. Trabanelli, V. Salvestrini, M. Baccarani and R. M. Lemoli: The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood, 113, 2394-2401 (2009)
68. + T regulatory cells. Blood, 109, 2871-2877 (2007) (Pubitemid 46482083)
69. Corm, S., C. Berthon, M. Imbenotte, V. Biggio, M. Lhermitte, C. Dupont, I. Briche and B. Quesnel: Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. Leuk Res, 33, 490-494 (2009)
70. Chamuleau, M. E., A. A. van de Loosdrecht, C. J. Hess, J. J. Janssen, A. Zevenbergen, R. Delwel, P. J. Valk, B. Lowenberg and G. J. Ossenkoppele: High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica, 93, 1894-1898 (2008)
71. Chung, D. J., M. Rossi, E. Romano, J. Ghith, J. Yuan, D. H. Munn and J. W. Young: Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood, 114, 555-563 (2009)
72. Okamoto, A., T. Nikaido, K. Ochiai, S. Takakura, M. Saito, Y. Aoki, N. Ishii, N. Yanaihara, K. Yamada, O. Takikawa, R. Kawaguchi, S. Isonishi, T. Tanaka and M. Urashima: Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res, 11, 6030-6039 (2005) (Pubitemid 41170335)
73. Brandacher, G., A. Perathoner, R. Ladurner, S. Schneeberger, P. Obrist, C. Winkler, E. R. Werner, G. Werner-Felmayer, H. G. Weiss, G. Gobel, R. Margreiter, A. Konigsrainer, D. Fuchs and A. Amberger: Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res, 12, 1144-1151 (2006) (Pubitemid 43342502)
74. Caligaris-Cappio, F. and P. Ghia: Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol, 26, 4497-4503 (2008)
75. Lauria, F., R. Foa, V. Mantovani, M. T. Fierro, D. Catovsky and S. Tura: T-cell functional abnormality in B-chronic lymphocytic leukaemia: evidence of a defect of the T-helper subset. Br J Haematol, 54, 277-283 (1983) (Pubitemid 13097411)
76. Foa, R., F. Lauria, P. Lusso, M. C. Giubellino, M. T. Fierro, M. L. Ferrando, D. Raspadori and L. Matera: Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia. Br J Haematol, 58, 509-516 (1984) (Pubitemid 14017200)
77. +CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood, 106, 2018-2025 (2005) (Pubitemid 41291715)
78. Giannopoulos, K., M. Schmitt, M. Kowal, P. Wlasiuk, A. Bojarska-Junak, J. Chen, J. Rolinski and A. Dmoszynska: Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep, 20, 677-682 (2008)
79. + CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma, 50, 788-801 (2009)
80. Ding, W., G. S. Nowakowski, T. R. Knox, J. C. Boysen, M. L. Maas, S. M. Schwager, W. Wu, L. E. Wellik, A. B. Dietz, A. K. Ghosh, C. R. Secreto, K. L. Medina, T. D. Shanafelt, C. S. Zent, T. G. Call and N. E. Kay: Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol, 147, 471-483 (2009)
81. +FoxP3+ regulatory T cells toward an antileukemia response. Leukemia, 22, 1007-1017 (2008) (Pubitemid 351689883)
82. Giannopoulos, K., A. Dmoszynska, M. Kowal, E. Wasik-Szczepanek, A. Bojarska-Junak, J. Rolinski, H. Dohner, S. Stilgenbauer and L. Bullinger: Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia, 23, 1771-1778 (2009)
83. Landgren, O., R. A. Kyle, R. M. Pfeiffer, J. A. Katzmann, N. E. Caporaso, R. B. Hayes, A. Dispenzieri, S. Kumar, R. J. Clark, D. Baris, R. Hoover and S. V. Rajkumar: Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood, 113, 5412-5417 (2009)
84. Dhodapkar, M. V., J. Krasovsky and K. Olson: T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci U S A, 99, 13009-13013 (2002)
85. Cohen, S., J. Haimovich and N. Hollander: Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. J Immunol, 182, 1667-1673 (2009)
86. Prabhala, R. H., P. Neri, J. E. Bae, P. Tassone, M. A. Shammas, C. K. Allam, J. F. Daley, D. Chauhan, E. Blanchard, H. S. Thatte, K. C. Anderson and N. C. Munshi: Dysfunctional T regulatory cells in multiple myeloma. Blood, 107, 301-304 (2006) (Pubitemid 43053555)
87. +CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood, 107, 3940-3949 (2006) (Pubitemid 43726800)
88. Feyler, S., M. von Lilienfeld-Toal, S. Jarmin, L. Marles, A. Rawstron, A. J. Ashcroft, R. G. Owen, P. J. Selby and G. Cook: CD4 (+)CD25 (+)FoxP3 (+) regulatory T cells are increased whilst CD3 (+)CD4 (-)CD8 (-)alphabetaTCR (+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol, 144, 686-695 (2009)
89. +FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica, 93, 423-430 (2008) (Pubitemid 351398644)
90. Kolb, H. J., C. Schmid, A. J. Barrett and D. J. Schendel: Graft-versus-leukemia reactions in allogeneic chimeras. Blood, 103, 767-776 (2004) (Pubitemid 38129531)
91. Bonifazi, F., A. de Vivo, G. Rosti, F. Guilhot, J. Guilhot, E. Trabacchi, R. Hehlmann, A. Hochhaus, P. C. Shepherd, J. L. Steegmann, H. C. Kluin-Nelemans, J. Thaler, B. Simonsson, A. Louwagie, J. Reiffers, F. X. Mahon, E. Montefusco, G. Alimena, J. Hasford, S. Richards, G. Saglio, N. Testoni, G. Martinelli, S. Tura and M. Baccarani: Chronic myeloid leukemia and interferonalpha: a study of complete cytogenetic responders. Blood, 98, 3074-3081 (2001)
92. Fujii, S.: Role of interferon-alpha and clonally expanded T cells in the immunotherapy of chronic myelogenous leukemia. Leuk Lymphoma, 38, 21-38 (2000) (Pubitemid 30224320)
93. Yang, X. F., C. J. Wu, S. McLaughlin, A. Chiliemi, K. S. Wang, C. Canning, E. p. Alyea, P. Kantoff, R. J. Soiffer, G. Dranoff and J. Ritz: CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci USA, 98, 7492-7497 (2001) (Pubitemid 32567976)
94. Yang, X. F., C. J. Wu, L. Chen, E. p. Alyea, C. Canning, P. Kantoff, R. J. Soiffer, G. Dranoff and J. Ritz: CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res, 62, 5517-5522 (2002)
95. Mumprecht, S., C. Schurch, J. Schwaller, M. Solenthaler and A. F. Ochsenbein: Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood, 114, 1528-1536(2009)
96. + regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J Immunol, 181, 6955-6963(2008)
97. Kiladjian, J. J., B. Cassinat, P. Turlure, N. Cambier, M. Roussel, S. Bellucci, M. L. Menot, G. Massonnet, J. L. Dutel, K. Ghomari, P. Rousselot, M. J. Grange, Y. Chait, W. Vainchenker, N. Parquet, L. Abdelkader-Aljassem, J. F. Bernard, J. D. Rain, S. Chevret, C. Chomienne and P. Fenaux: High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood, 108, 2037-2040(2006) (Pubitemid 44395018)
98. Kiladjian, J. J., B. Cassinat, S. Chevret, P. Turlure, N. Cambier, M. Roussel, S. Bellucci, B. Grandchamp, C. Chomienne and P. Fenaux: Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 112, 3065-3072 (2008)
99. +CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood, 110, 847-850 (2007) (Pubitemid 47267420)
100. + FOXP3+ T regulatory cells in acquired aplastic anemia. Blood, 110, 1603-1606 (2007) (Pubitemid 47443977)